Preclinical pharmacology of milnacipran

  title={Preclinical pharmacology of milnacipran},
  author={Michael S. Briley and Jean-François Prost and Chantal Moret},
  journal={International Clinical Psychopharmacology},
Milnacipran (Ixel) is a new antidepressant which has been developed for its selective inhibition of both serotonin and noradrenaline reuptake and its lack of affinity for neurotransmitter receptors. It inhibits virtually equipotently the reuptake of serotonin and noradrenaline both in vitro and in vivo, as demonstrated by the antagonism of centrally acting monoamine displacers. It has no effect on dopamine reuptake. In addition, milnacipran has been shown by intracerebral microdialysis to… 
Milnacipran: an antidepressant with dual selectivity of action on noradrenaline and serotonin uptake
Milnacipran appears to be an antidepressant with a very favourable benefit/risk ratio and has proved to be a very safe drug with a benign adverse event profile clearly superior to that of TCAs and, to a certain extent, that of SSRIs.
Milnacipran: Beyond a Role of Antidepressant
Evidence suggests that milnacipran is effective and tolerable in the treatment of fibromyalgia and may have usefulness for fatigue and anxiety symptoms and future directions of research are identified.
Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic effect of tramadol in rats with mononeuropathic pain
Milnacipran has an antihyperalgesic effect mediated by serotonergic, noradrenergic and opioidergic systems and the combined use of tramadol with milnacIPran potentiates the effect of Tramadol in the management of neuropathic pain.
Milnacipran, a Well-Tolerated Specific Serotonin and Norepinephrine Reuptake Inhibiting Antidepressant
Milnacipran1 was developed as a new specific serotonin and norepinephrine reuptake inhibitor (SNRI) with the intention of providing greater antidepressant efficacy than the SSRIs without the side effects of the TCA, and the preclinical properties, pharmacokinetics, and principal clinical and safety data are reviewed.
Milnacipran. A review of its use in depression.
Although further published data are required to confirm its efficacy, good tolerability profile and pharmacokinetic profile which suggests a low potential for drug interactions, milnacipran should be considered a promising agent for the treatment of patients with major depressive disorder.
Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy and tolerability
A new class of antidepressants that inhibit selectively the reuptake of both serotonin and noradrenaline with no affinity for the receptors responsible for the adverse effects of the TCAs appears to offer a potential useful addition to the therapeutic arsenal of antidepressant drugs.
Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan
Japan represents a unique situation because in 1999 milnacipran was launched within months of the first SSRI and is still the only SNRI in Japan together with only two SSRIs (a third has just been introduced).
Effect of milnacipran on extracellular monoamine concentrations in the medial prefrontal cortex of rats pre-treated with lithium.
Lithium carbonate might augment the antidepressant effects of serotonin-noradrenaline reuptake inhibitors by augmenting serotonin release, in the rat medial prefrontal cortex.
Effects of Milnacipran and Pindolol on Extracellular Noradrenaline and Serotonin Levels in Guinea Pig Hypothalamus
It is indicated that milnacipran, by blocking the uptake of NA and 5‐HT, increases virtually equipotently the extracellular levels ofNA and 5-HT, confirming previous in vitro studies.
Dual serotonin and noradrenaline reuptake inhibitors: Focus on their differences
  • P. Blier
  • Medicine
    International journal of psychiatry in clinical practice
  • 2006
In the treatment of depression, SNRIs appear to have similar effectiveness and when compared to selective 5-HT reuptake inhibitors, they generally exert a superior antidepressant effect, suggesting that individual patients not responding to a SNRI may present a favourable response to another agent within that family.